Effects of VitabridC¹²on Skin Inflammation

Abstract

BackgroundVitabridC12 is newly developed and composed of vitamin C and Vitabrid (lamellar, hydrated zinc oxide).ObjectiveIn this study, we aimed to investigate the effects of VitabridC12 on psoriasis and atopic dermatitis.MethodsMice with imiquimod-induced psoriasis or Dermatophagoides farinae-induced atopic dermatitis were applied with VitabridC12. The effects of VitabridC12 were evaluated by clinical features, histology, and immunologic features by examining cytokines and chemokines.ResultsIn psoriasis model, VitabridC12 decreased epidermal thickness and reduced inflammatory cell infiltration. In atopic dermatitis model, VitabridC12 decreased dermal infiltration of inflammatory cells, epidermal hyperplasia, and hyperkeratosis. VitabridC12 reduced the expression levels of proinflammatory mediators such as interleukin (IL)-1β, IL-6, IL-8, IL-17A, IL-22, tumor necrosis factor-α, CXCL1, CCL17, and CCL20 as well as COX-2 in imiquimod-induced psoriatic skin lesions. Likewise, VitabridC12 reduced the expression levels of IL-4, IL-5, IL-13, thymic stromal lymphopoietin, and CCL4 in D. farinae-induced skin lesions, and decreased the serum immunoglobulin E level in the atopic dermatitis mouse model. Particularly, the VitabridC12-treated mice showed downregulated expressions of mitogen-activated protein kinase (MAPK), including extracellular signal-regulated kinase (ERK), p38, and MAPK/ERK kinase, as well as inhibited phosphorylation of nuclear factor-κB p65.ConclusionTaken together, these findings indicate that VitabridC12 exhibits anti-inflammatory activities and is a promising candidate as a treatment option for psoriasis or atopic dermatitis.

Coencapsulation of Immunosuppressive Drug with Anti-Inflammatory Molecule in Pickering Emulsions as an Innovative Therapeutic Approach for Inflammatory Dermatoses

“…To confirm the alleviation of psoriatic lesions, the expression of psoriasis-associated genes were quantified from skin biopsies using microfluidic qPCR ( Figure 5 c). Compared with IMQ group, topical application of pickering emulsions, except E-CT, significantly decreased the expression of T-cell markers (CD3, CD4, CD8) and T-cell chemokines CCL17 and CCL20 ( Lee et al, 2017 ), suggesting reduced cutaneous T-cell infiltration. Concomitantly, the decreased expressions of genes associated with keratinocytes, including K6a , S100a8 , and LL37 , were associated with the decreased expressions of psoriasis-associated proinflammatory cytokines (IL-17A, IL-17F, IL-36α, and TNF-α) ( Blauvelt and Chiricozzi, 2018 ; Christmann et al, 2020 ; Gao et al, 2020 ).…”

NXP081, DNA Aptamer–Vitamin C Complex Ameliorates DNFB-Induced Atopic Dermatitis in Balb/c Mice

“…Several studies have shown that vitamin C administration can attenuate mast-cell-mediated bronchial hypersensitivity or allergies [22]. Furthermore, in cases of AD caused by house mites, the application of a topical ointment containing a combination of vitamin C and zinc oxide has been observed to decrease the presence of mast cells in the skin of mice that have been exposed to mites [23]. In a manner similar to the previously mentioned reports, the migration of mast cells was significantly reduced in the groups that received dose-dependent amounts of NXP081 (Figure 4A,B).…”

Topical micronutrients in atopic dermatitis-An evidence-based review

“…Because ZnO has its own anti‐inflammatory, antioxidant, and antimicrobial effects that could influence the results (Jones, Ray, Ranjit, & Manna, ), the group investigated the difference in inflammatory serum markers between the ZnO vehicle (Vitabrid) compared with VitabridC 12 . VitabridC 12 treated mice had significantly decreased expression of pro‐inflammatory IL‐4 and chemokine ligand 4 (CCL4) and pro‐allergic cytokine thymic stromal lymphopoietin (TSLP) ( p < .05), compared with Vitabrid (Lee et al, ). These are promising results that deserve further exploration in clinical trials.…”

“…Despite its positive antioxidant benefits, vitamin C is unstable, easily oxidized, and does not easily penetrate into the dermis. To overcome these limitations, zinc oxide (ZnO) has been compounded with vitamin C. Its hydrophobic exterior allows the formulation to penetrate target tissues and consistently release vitamin C for longer than 12 hr (Lee, Jeon, Choi, Kim, & Kim, ). Using a mouse model of house mite‐induced AD, daily application of vitamin C‐zinc oxide complex cream (VitabridC 12 ) for 6 days significantly decreased epidermal thickness ( p < .05) and reduced mast cells ( p < .05) compared with the control group that were not treated with any cream.…”